PhenoCycler®
The PhenoCycler ® is a cutting-edge fluidics control unit that integrates with the PhenoImager Fusion imaging platform creating the fastest spatial biology solution with unparalleled throughput.
Akoya Biosciences, 'The Spatial Biology Company', is committed to developing powerful imaging tools to enable scientists and clinical researchers gain a better understanding of complex diseases such as cancer. The company offers the most comprehensive end-to-end solution for high-parameter tissue analysis from discovery through clinical and translational research, enabling more precise therapies for immuno-oncology and other drug development applications. Akoya’s CODEX platform enables the assessment of more than 40 markers and is ideally suited for biomarker discovery. The company’s Phenoptics platform provides the assay robustness and throughput necessary for translational and clinical research required in clinical trials.
The PhenoCycler ® is a cutting-edge fluidics control unit that integrates with the PhenoImager Fusion imaging platform creating the fastest spatial biology solution with unparalleled throughput.
PhenoImager ® HT (formerly Vectra ® Polaris™) is the fastest and most highly cited whole-slide, single-cell resolution imaging platform for spatial phenotyping and the development of spatial signat...
The PhenoImager ® ; Fusion system is a whole-slide, single-cell resolution, ultrafast multispectral imager ideal for standard throughput brightfield and fluorescence imaging applications. This imagin...
inForm® Tissue Finder™ adds exceptional functionality to inForm Cell Analysis to automate the detection and segmentation of specific tissues through powerful patented pattern recognition algorithms....
Akoya Biosciences, 'The Spatial Biology Company', is committed to developing powerful imaging tools to enable scientists and clinical researchers gain a better understanding of complex diseases such as cancer. The company offers the most comprehensive end-to-end solution for high-parameter tissue analysis from discovery through clinical and translational research, enabling more precise therapies for immuno-oncology and other drug development applications. Akoya’s CODEX platform enables the assessment of more than 40 markers and is ideally suited for biomarker discovery. The company’s Phenoptics platform provides the assay robustness and throughput necessary for translational and clinical research required in clinical trials.